-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Q4p5wXXSAHQGjcRAMSWt+3l7lmAhgw1oT87WKPi11oZlxJhHpdma7kZuuShkq5lc NXjy6Q9kzERQB5C8ISoMew== 0001021408-02-002414.txt : 20020414 0001021408-02-002414.hdr.sgml : 20020414 ACCESSION NUMBER: 0001021408-02-002414 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020214 GROUP MEMBERS: ANSELM LEUNG GROUP MEMBERS: BIOASIA INVESTMENTS LLC GROUP MEMBERS: BIOTECHNOLOGY DEVELOPMENT FUND III GROUP MEMBERS: BIOTECHNOLOGY DEVELOPMENT FUND, LP GROUP MEMBERS: EDGAR ENGLEMAN GROUP MEMBERS: FRANK F.C., KUNG SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AMERICAN PHARMACEUTICAL PARTNERS INC /CA/ CENTRAL INDEX KEY: 0001141399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680389419 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-78076 FILM NUMBER: 02549346 BUSINESS ADDRESS: STREET 1: 10866 WILSHIRE BLVD STREET 2: SUITE 1270 CITY: LOS ANGELES STATE: CA ZIP: 90024 MAIL ADDRESS: STREET 1: 10866 WILSHIRE BLVD STREET 2: SUITE 1270 CITY: LOS ANGELES STATE: CA ZIP: 90024 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOASIA INVESTMENTS LLC CENTRAL INDEX KEY: 0001103307 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 575 HIGH STREET SUITE 201 CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: 6506880821 MAIL ADDRESS: STREET 1: 575 HIGH STREET STE 201 CITY: PALO ALTO STATE: CA ZIP: 94301 SC 13G 1 dsc13g.txt SCHEDULE 13G OMB APPROVAL OMB Number: 3235-0145 Expires: October 31, 2002 Estimated average burden hours per response 14.9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 American Pharmaceutical Partners, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02889P 10 9 (CUSIP Number) December 14, 2001 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-l(b) [_] Rule 13d-l(c) [X] Rule 13d-l(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 02889P 10 9 - ------------------------------------------------------------------------------ 1. Names of Reporting Persons. Biotechnology Development Fund, L.P. ("BDF") I.R.S. Identification Nos. of above persons (entities only). 94-3258409 - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [_] (b) [x] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Citizenship or Place of Organization Delaware - ------------------------------------------------------------------------------ Number of 5. Sole Voting Power 940,345* Shares ------------------------------------------------ Beneficially 6. Shared Voting Power 1,880,690** Owned by ------------------------------------------------ Each 7. Sole Dispositive Power 940,345* Reporting ------------------------------------------------ Person With 8. Shared Dispositive Power 1,880,690** - ------------------------------------------------------------------------------ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,821,035 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_]. Not applicable. 11. Percent of Class Represented by Amount in Row (9) 5.8% 12. Type of Reporting Person (See Instructions) PN * Except that BioAsia, the General Partner of BDF, and Kung, Leung and Engleman, members of BioAsia, may be deemed to have shared voting and investment power over these shares. ** BDF III directly owns these shares. BDF may be deemed to have shared power to vote and dispose of these shares through a 24.8% limited partnership interest in BDF III. CUSIP No. 02889P 10 9 - ------------------------------------------------------------------------------ 1. Names of Reporting Persons. Biotechnology Development Fund III, L.P. ("BDF III") I.R.S. Identification Nos. of above persons (entities only). 77-0474834 - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [_] (b) [x] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Citizenship or Place of Organization Delaware - ------------------------------------------------------------------------------ Number of 5. Sole Voting Power 1,880,690 Shares ------------------------------------------------ Beneficially 6. Shared Voting Power 0 Owned by ------------------------------------------------ Each 7. Sole Dispositive Power 1,880,690 Reporting ------------------------------------------------ Person With 8. Shared Dispositive Power 0 - ------------------------------------------------------------------------------ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,880,690*** 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_]. Not applicable. 11. Percent of Class Represented by Amount in Row (9) 3.9% 12. Type of Reporting Person (See Instructions) PN *** Except that BioAsia, the General Partner of BDF, and Kung, Leung and Engleman, members of BioAsia, may be deemed to have shared power to vote and dispose of these shares. CUSIP No. 02889P 10 9 - ------------------------------------------------------------------------------ 1. Names of Reporting Persons. BioAsia Investments, LLC ("BioAsia") I.R.S. Identification Nos. of above persons (entities only). 94-3258407 - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [_] (b) [x] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Citizenship or Place of Organization California - ------------------------------------------------------------------------------ Number of 5. Sole Voting Power 0 Shares ------------------------------------------------ Beneficially 6. Shared Voting Power 2,821,035 Owned by ------------------------------------------------ Each 7. Sole Dispositive Power 0 Reporting ------------------------------------------------ Person With 8. Shared Dispositive Power 2,821,035 - ------------------------------------------------------------------------------ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,821,035**** 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_]. Not applicable. 11. Percent of Class Represented by Amount in Row (9) 5.8% 12. Type of Reporting Person (See Instructions) OO **** Includes 1,880,690 shares directly owned by BDF III and 940,345 shares directly owned by BDF. As the General Partner of BDF and BDF III, BioAsia may be deemed to have shared power to vote and dispose of these shares. CUSIP No. 02889P 10 9 - ------------------------------------------------------------------------------ 1. Names of Reporting Persons. Frank F.C. Kung ("Kung") I.R.S. Identification Nos. of above persons (entities only). - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [_] (b) [X] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Citizenship or Place of Organization United States - ------------------------------------------------------------------------------ Number of 5. Sole Voting Power 30,000 Shares ------------------------------------------------ Beneficially 6. Shared Voting Power 2,821,035 Owned by ------------------------------------------------ Each 7. Sole Dispositive Power 30,000 Reporting ------------------------------------------------ Person With 8. Shared Dispositive Power 2,821,035 - ------------------------------------------------------------------------------ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,851,035, which includes 25,000 shares purchasable under an incentive stock option and 5,000 shares held directly by Mr. Kung, 1,880,690 shares directly owned by BDF III and 940,345 shares directly owned by BDF. Mr. Kung is a member of BioAsia and may be deemed to have shared power to vote and dispose of the shares owned by BDF and BDF III. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_]. Not applicable. 11. Percent of Class Represented by Amount in Row (9) 5.8% 12. Type of Reporting Person (See Instructions) IN CUSIP No. 02889P 10 9 - ------------------------------------------------------------------------------ 1. Names of Reporting Persons. Anselm Leung ("Leung") I.R.S. Identification Nos. of above persons (entities only). - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [_] (b) [X] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Citizenship or Place of Organization United States - ------------------------------------------------------------------------------ Number of 5. Sole Voting Power 5,000 Shares ------------------------------------------------ Beneficially 6. Shared Voting Power 2,821,035 Owned by ------------------------------------------------ Each 7. Sole Dispositive Power 5,000 Reporting ------------------------------------------------ Person With 8. Shared Dispositive Power 2,821,035 - ------------------------------------------------------------------------------ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,826,035, which includes 5,000 shares directly owned by Mr. Leung, 1,880,690 shares directly owned by BDF III and 940,345 shares directly owned by BDF. Mr. Leung is a member of BioAsia and may be deemed to have shared power to vote and dispose of the shares owned by BDF and BDF III. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_]. Not applicable. 11. Percent of Class Represented by Amount in Row (9) 5.8% 12. Type of Reporting Person (See Instructions) IN CUSIP No. 02889P 10 9 - ------------------------------------------------------------------------------ 1. Names of Reporting Persons. Edgar Engleman ("Engleman") I.R.S. Identification Nos. of above persons (entities only). - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [_] (b) [X] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Citizenship or Place of Organization United States - ------------------------------------------------------------------------------ Number of 5. Sole Voting Power 3,000 Shares ------------------------------------------------ Beneficially 6. Shared Voting Power 2,821,035 Owned by ------------------------------------------------ Each 7. Sole Dispositive Power 3,000 Reporting ------------------------------------------------ Person With 8. Shared Dispositive Power 2,821,035 - ------------------------------------------------------------------------------ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,824,035, which includes 3,000 shares directly owned by Mr. Engleman, 1,880,690 shares directly owned by BDF III and 940,345 shares directly owned by BDF. Mr. Engleman is a member of BioAsia and may be deemed to have shared power to vote and dispose of the shares owned by BDF and BDF III. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_]. Not applicable. 11. Percent of Class Represented by Amount in Row (9) 5.8% 12. Type of Reporting Person (See Instructions) IN Item 1. (a) Name of Issuer American Pharmaceutical Partners, Inc. (b) Address of Issuer's Principal Executive Offices 11777 San Vicente Blvd., Suite 550 Los Angeles, CA 90049 Item 2. (a) Name of Person Filing This Schedule 13G is being filed on behalf of the following persons (the "Reporting Persons"): i. Biotechnology Development Fund, L.P. ii. Biotechnology Development Fund III, L.P. iii. BioAsia Investments, LLC iv. Frank F.C. Kung v. Anselm Leung vi. Edgar Engleman BioAsia is the general partner of BDF and BDF III, and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by BDF and BDF III, or beneficially owned by BDF through a 24.8% limited partnership interest in BDF III. Kung, Leung and Engleman are members of BioAsia, and may be deemed to have indirect beneficial ownership of the shares of the issuer directly and indirectly owned by BDF and directly owned by BDF III. BioAsia disclaims any beneficial ownership of the issuer directly owned by BDF and BDF III except to the extent of any indirect pecuniary interest therein. Kung, Leung and Engleman hereby disclaim beneficial ownership of the shares held by BDF and BDF III except to the extent of any respective indirect pecuniary interest therein. Mr. Kung is a member of the Board of Directors of the issuer. Attached as Exhibit A is a copy of a Joint Filing Agreement by and among the Reporting Persons set forth above that this Schedule 13G is being filed on behalf of each Reporting Person. (b) Address of Principal Business Office or, if none, Residence The principal business office of each of the Reporting Persons comprising the group filing this Schedule 13G is located at 575 High Street, Suite 201, Palo Alto, CA 94301. (c) Citizenship i. BDF is a Delaware limited partnership. ii. BDF III is a Delaware limited partnership. iii. BioAsia is a California limited liability company. iv. Mr. Kung is a United States citizen. v. Mr. Leung is a United States citizen. vi. Mr. Engleman is a United States citizen. (d) Title of Class of Securities Common Stock, par value $0.001 per share. (e) CUSIP Number 02889P 10 9 Item 3. If this statement is filed pursuant to ss.ss.240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable. Item 4. Ownership. The information in item 1 and items 5 through 11 on the cover pages (pp. 2 - 7) on this Schedule 13G is hereby incorporated into this item 4 by reference. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. Item 6. Ownership of More than Five Percent on Behalf of Another Person. Under certain circumstances set forth in the limited partnership agreements of BDF and BDF III and the limited liability company operating agreement of BioAsia, the general and limited partners of BDF and BDF III and the members of BioAsia each may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the issuer owned by each such entity of which they are a partners or a member, as applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification SIGNATURES After reasonable inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: February 12, 2002 BIOTECHNOLOGY DEVELOPMENT FUND, L.P. By: BIOASIA INVESTMENTS, LLC its General Partner By: /s/ Frank F.C. Kung ---------------------- Frank F.C. Kung Managing Member BIOTECHNOLOGY DEVELOPMENT FUND III, L.P. By: BIOASIA INVESTMENTS, LLC its General Partner By: /s/ Frank F.C. Kung ---------------------- Frank F.C. Kung Managing Member BIOASIA INVESTMENTS, LLC By: /s/ Frank F.C. Kung ---------------------- Frank F.C. Kung Managing Member By: /s/ Frank F.C. Kung ---------------------- Frank F.C. Kung By: /s/ Anselm Leung ------------------- Anselm Leung By: /s/ Edgar Engleman --------------------- Edgar Engleman EXHIBIT INDEX Exhibit A: Joint Filing Agreement dated February 12, 2002, by and among Biotechnology Development Fund, L.P., and Biotechnology Development Fund III, L.P., BioAsia Investments, LLC, Frank F. C. Kung, Anselm Leung and Edgar Engleman. Exhibit A JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) ----------------------------- The undersigned acknowledge and agree that the foregoing statement of Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that it knows or has reason to believe that such information is inaccurate. Dated: February 12, 2002 BIOTECHNOLOGY DEVELOPMENT FUND, L.P. By: BIOASIA INVESTMENTS, LLC its General Partner By: /s/ Frank F.C. Kung ---------------------- Frank F.C. Kung Managing Member BIOTECHNOLOGY DEVELOPMENT FUND III, L.P. By: BIOASIA INVESTMENTS, LLC its General Partner By: /s/ Frank F.C. Kung ---------------------- Frank F.C. Kung Managing Member BIOASIA INVESTMENTS, LLC By: /s/ Frank F.C. Kung ---------------------- Frank F.C. Kung Managing Member By: /s/ Frank F.C. Kung ---------------------- Frank F.C. Kung By: /s/ Anselm Leung ------------------- Anselm Leung By: /s/ Edgar Engleman --------------------- Edgar Engleman -----END PRIVACY-ENHANCED MESSAGE-----